XLO
Xilio Therapeutics, Inc.
$8.31
+4.01%
$54.6M
No data for this timeframe.
Vol
Market Cap$54.6M
Cap SizeMicro Cap
Inst. Holders9 funds
Inst. Value$2.6M
Insider Activity2B / 0S
Insider Net $$2.0M
Reddit Sentiment33° Cool
SEC Reports6
Press Releases3
Recent Activity
Jun 11, 2026
Insider
Curran Daniel J. was granted 5,000 shares
Director
Jun 11, 2026
Insider
Bello Akintunde Olatokumbo was granted 5,000 shares
Director
Jun 11, 2026
Insider
ROSS ROBERT W. was granted 5,000 shares
Director
Jun 1, 2026
SEC
Xilio Therapeutics' S-3 shelf registration (File No. 333-295785) became effective on May 29, 2026, allowing the company
EFFECT — Impact 5/10
May 27, 2026
SEC
Xilio Therapeutics filed Amendment No. 1 to its S-3 shelf registration, registering up to $250M in securities (common, p
S-3/A — Impact 4/10
May 12, 2026
SEC
Xilio Therapeutics reported Q1 2026 collaboration and license revenue of $12.6M (up from $2.9M YoY) and a net loss of $9
8-K — Impact 4/10
May 12, 2026
earnings
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
<p align="center"><em>On track for planned IND submission in mid-2026 and Phase 1 initiation in the
Apr 17, 2026
Press
Xilio Therapeutics released preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, demonstrating tumor
Impact 5/10
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$20.00 (Aug 2025)
Current $8.31
Low $20.00
Median $20.00
High $20.00
1 analysts
$20.00
$20.00
Analyst Ratings
2Strong Buy
2Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 6, 2025 | Leerink Partners | INITIATE | Outperform |
| Nov 8, 2024 | Raymond James | MAINTAIN | Outperform → Outperform |
| May 30, 2023 | Chardan Capital | REITERATE | Buy → Buy |
| May 11, 2023 | Chardan Capital | REITERATE | Buy |
| Jan 27, 2023 | Morgan Stanley | MAINTAIN | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.59 ▼ -1.7% | $-0.59 — $-0.59 | 74% YoY | 1 |
| Next Q | $-0.92 ▼ -61.4% | $-0.92 — $-0.92 | 40% YoY | 1 |
| Current FY | $-3.02 ▼ -26.4% | $-3.02 — $-3.02 | 28% YoY | 1 |
| Next FY | $-2.59 ▼ -819.4% | $-2.59 — $-2.59 | 14% YoY | 1 |
Latest Reports
BEARISH
EFFECT
5/10
Xilio Therapeutics' S-3 shelf registration (File No. 333-295785) became effective on May 29, 2026, allowing the company
Jun 1, 2026
NEUTRAL
S-3/A
4/10
Xilio Therapeutics filed Amendment No. 1 to its S-3 shelf registration, registering up to $250M in securities (common, p
May 27, 2026
MIXED
Press
5/10
Xilio Therapeutics released preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, demonstrating tumor
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.0M | — |
| MORGAN STANLEY | $483.5K | — |
| RENAISSANCE TECHNOLOGIES LLC | $416.9K | — |
| FMR LLC | $307.5K | — |
| VANGUARD FIDUCIARY TRUST CO | $239.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | Curran Daniel | A | $0.00 |
| Jun 11, 2026 | Bello Akintunde | A | $0.00 |
| Jun 11, 2026 | ROSS ROBERT | A | $0.00 |
| Jun 11, 2026 | Bonstein Sara | A | $0.00 |
| Jun 11, 2026 | Xu Yuan | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
9 institutional holders with $2.6M total value (313,570 shares) as of 2026-Q1. Top holders: VANGUARD, MORGAN, RENAISSANCE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 123,660 | $1.0M | 39.4% | — |
| 2 | MORGAN STANLEY | 57,493 | $483.5K | 18.3% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 49,566 | $416.9K | 15.8% | — |
| 4 | FMR LLC | 36,558 | $307.5K | 11.7% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 28,475 | $239.5K | 9.1% | — |
| 6 | STATE STREET CORP | 13,311 | $111.9K | 4.2% | — |
| 7 | CWM, LLC | 4,206 | $35.4K | 1.3% | — |
| 8 | Vanguard Global Advisers, LLC | 210 | $1.8K | 0.1% | — |
| 9 | ROYAL BANK OF CANADA | 91 | $1.0K | 0.0% | — |
9 unique insiders with 10 transactions. Net insider value: $2.0M ($2.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Curran Daniel J. | Director | AWARD | 5,000 | — | — |
| Jun 11, 2026 | Bello Akintunde Olatokumbo | Director | AWARD | 5,000 | — | — |
| Jun 11, 2026 | ROSS ROBERT W. | Director | AWARD | 5,000 | — | — |
| Jun 11, 2026 | Bonstein Sara | Director | AWARD | 5,000 | — | — |
| Jun 11, 2026 | Xu Yuan | Director | AWARD | 5,000 | — | — |
| Jun 11, 2026 | Shannon James Samuel | Director | AWARD | 5,000 | — | — |
| Jun 11, 2026 | Brennan Aoife | Director | AWARD | 5,000 | — | — |
| Apr 15, 2026 | Blanchard Cheryl R | Director | AWARD | 10,000 | — | — |
| Mar 26, 2026 | Shannon James Samuel | Director | BUY | 5,000 | $8.79 | $43.9K |
| Feb 13, 2026 | GILEAD SCIENCES, INC. | 10%+ Owner | BUY | 3,739,000 | $0.5349 | $2.0M |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.2/10.
BEARISH
EFFECT
5/10
Xilio Therapeutics' S-3 shelf registration (File No. 333-295785) became effective on May 29, 2026, a
Jun 1, 2026
NEUTRAL
S-3/A
4/10
Xilio Therapeutics filed Amendment No. 1 to its S-3 shelf registration, registering up to $250M in s
May 27, 2026
NEUTRAL
8-K
4/10
Xilio Therapeutics reported Q1 2026 collaboration and license revenue of $12.6M (up from $2.9M YoY)
May 12, 2026
BULLISH
PRESS-RELEASE
7/10
Xilio Therapeutics reported Q1 2026 results with collaboration revenue of $12.6M (up from $2.9M a ye
May 12, 2026
NEUTRAL
3
2/10
Cheryl Blanchard, a reporting person at Xilio Therapeutics, filed a Form 3 indicating initial benefi
Apr 16, 2026
NEUTRAL
8-K
3/10
Xilio Therapeutics appointed Cheryl R. Blanchard, Ph.D., to its Board of Directors and Compensation
Apr 16, 2026
MIXED
5/10
Xilio Therapeutics released preclinical data for XTX601, a masked T cell engager targeting CLDN18.2,
Apr 17, 2026
BULLISH
8/10
Xilio Therapeutics reported strong financial results for Q4 and full year 2025, driven by a $17.5M m
Mar 23, 2026
NEUTRAL
4/10
Xilio Therapeutics announced an upcoming poster presentation at the AACR Annual Meeting in April 202
Mar 17, 2026
Historical analyst distribution (last covering-analyst action Aug 2025): 80% buy across 5 analysts — 2 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$20.00 mean target (Aug 2025)
$20.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $8.31 |
| Target Low | $20.00 |
| Target Mean | $20.00 |
| Target Median | $20.00 |
| Target High | $20.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.59 | $-0.59 | $-0.59 | 73.7% | -1.7% | — | $0.0B | 57.4% | 1 |
| Next Q 2026-09-30 |
$-0.92 | $-0.92 | $-0.92 | 40.3% | -61.4% | — | $0.0B | -69.9% | 1 |
| Current FY 2026-12-31 |
$-3.02 | $-3.02 | $-3.02 | 27.9% | -26.4% | 0↑ 1↓ | $0.0B | -17.7% | 1 |
| Next FY 2027-12-31 |
$-2.59 | $-2.59 | $-2.59 | 14.2% | -819.4% | 0↑ 1↓ | $0.0B | -20.7% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.590 | |
| 7d ago | $-0.580 | -0.010 |
| 30d ago | $-0.580 | -0.010 |
| 60d ago | $0.000 | -0.590 |
| 90d ago | $-1.960 | +1.370 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 6, 2025 | Leerink Partners | INITIATE | — | Outperform |
| Nov 8, 2024 | Raymond James | MAINTAIN | Outperform | Outperform |
| May 30, 2023 | Chardan Capital | REITERATE | Buy | Buy |
| May 11, 2023 | Chardan Capital | REITERATE | — | Buy |
| Jan 27, 2023 | Morgan Stanley | MAINTAIN | — | Overweight |
| Dec 21, 2022 | Chardan Capital | INITIATE | — | Buy |
| Nov 10, 2022 | Raymond James | MAINTAIN | — | Outperform |
| Aug 10, 2022 | Morgan Stanley | MAINTAIN | — | Overweight |
| Jan 10, 2022 | HC Wainwright & Co. | INITIATE | — | Buy |
| Nov 16, 2021 | Raymond James | INITIATE | — | Outperform |
| Nov 16, 2021 | Cowen & Co. | INITIATE | — | Outperform |
| Nov 16, 2021 | Morgan Stanley | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$XLO will present on Monday, they need to trade above $1
▲ 1
💬 1
⚡ 0.5
May 29, 2026
Clinical Trial
XTX202 in Patients With Advanced Solid Tumors
Phase Phase 2 — COMPLETED
May 12, 2026
earnings
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
<p align="center"><em>On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-i
May 11, 2026
earnings_calendar
XLO Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
earnings_calendar
XLO Q1 2026 Earnings Scheduled — 2026-05-08
May 7, 2026
other
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company d
May 7, 2026
earnings_calendar
XLO Q1 2026 Earnings Scheduled — 2026-05-07
Apr 17, 2026
fda
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
<p align="center"><em>XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models
Apr 16, 2026
other
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
<p align="justify">WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company
Apr 3, 2026
other
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company
Mar 23, 2026
earnings
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
<p align="center"><em>XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 ini
Mar 17, 2026
fda
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
<p align="justify">WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company
Mar 12, 2026
other
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
<p align="justify">WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company
Mar 9, 2026
earnings_calendar
XLO Q4 2025 Earnings After Market Close — 2026-03-09
Mar 4, 2026
earnings_calendar
XLO Q4 2025 Earnings After Market Close — 2026-03-04
Mar 2, 2026
other
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company